A single-center analysis of patients with extranodal marginal zone lymphoma of the breast

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, (eds.). et al. WHO classification of tumours of haematopoietic and lymphoid tissues. revised 4th edn. Lyon; International Agency for Research on Cancer (IARC); 2017.
   Google Scholar
• Sriskandarajah P, Dearden CE. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1-2):84–91.
   PubMed Web of Science ®Google Scholar
• Armitage JO. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa‐associated lymphoid tissue. Cancer. 1984;53(11):2515–2524.
   PubMed Web of Science ®Google Scholar
• Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–3044.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51–60.
   PubMedGoogle Scholar
• Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014;165(1):67–77.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Ryan G, Seymour JF, et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the international extranodal lymphoma study group. Ann Oncol. 2009;20(12):1993–1999.
   PubMed Web of Science ®Google Scholar
• Husnain M, Kuker R, Reis IM, et al. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: a single center analysis. Cancer Med. 2020;9(14):5051–5064.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Ponzoni M. Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches. Pathology. 2020;52(1):15–29.
   PubMed Web of Science ®Google Scholar
• Travaglino A, Pace M, Varricchio S, et al. Hashimoto thyroiditis in primary thyroid Non-Hodgkin lymphoma. Am J Clin Pathol. 2020;153(2):156–164.
   PubMed Web of Science ®Google Scholar
• Florindez JA, Alderuccio JP, Reis IM, et al. Primary thyroid lymphoma: survival analysis of SEER database (1995–2016). Leuk Lymphoma. 2021;1–4.
   Google Scholar
• Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013;98(8):3131–3138.
   PubMed Web of Science ®Google Scholar
• Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North america. Am J Surg Pathol. 2006;30(12):1546–1553.
   PubMed Web of Science ®Google Scholar
• Ha CS, Dubey MD, Praveen MD, et al. Localized primary Non-Hodgkin lymphoma of the breast. Am J Clin Oncol. 1998;21(4):376–380.
   PubMed Web of Science ®Google Scholar
• Giardini R, Piccolo C, Rilke F. Primary non‐hodgkin's lymphomas of the female breast. Cancer. 1992;69(3):725–735.
   PubMed Web of Science ®Google Scholar
• Liguori G, Cantile M, Cerrone M, et al. Breast MALT lymphomas: a clinicopathological and cytogenetic study of 9 cases. Oncol Rep. 2012;28(4):1211–1216.
   PubMed Web of Science ®Google Scholar
• Ludmir EB, Milgrom SA, Pinnix CC, et al. Emerging treatment strategies for primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Clin Lymphoma Myeloma Leuk. 2019;19(4):244–250.
   PubMed Web of Science ®Google Scholar
• Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009;84(3):133–139.
   PubMed Web of Science ®Google Scholar
• Carbone P, Kaplan H, Musshoff K, et al. Report of the committee on hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409–1417.
   PubMed Web of Science ®Google Scholar
• Bacon CM, Du MQ, Dogan A. Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. J Clin Pathol. 2007;60(4):361–372.
   PubMed Web of Science ®Google Scholar
• Falini B, Agostinelli C, Pileri SA, et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61(5):930–941.
   PubMed Web of Science ®Google Scholar
• Genco I, Gur H, Hajiyeva S. Lymphoma of the breast: a clinicopathologic analysis of 51 cases with a specific emphasis on patients with a history of breast carcinoma. Breast J. 2021;27(5):456–460.
   PubMed Web of Science ®Google Scholar
• Cuff K, Dettrick A, Chern B. Synchronous breast cancer and lymphoma: a case series and a review of the literature. J Clin Pathol. 2010;63(6):555–557.
   PubMed Web of Science ®Google Scholar
• Yang WT, Lane D, Le-Petross H, et al. Breast lymphoma: Imaging findings of 32 tumors in 27 patients. Radiology. 2007;245(3):692–702.
   PubMed Web of Science ®Google Scholar
• Raj SD, Shurafa M, Shah Z, et al. Primary and secondary breast lymphoma: Clinical, pathologic, and multimodality imaging review. Radiographics. 2019;39(3):610–625.
   PubMed Web of Science ®Google Scholar
• Thomas A, Link B, Altekruse S, et al. Primary breast lymphoma in the United States: 1975–2013. J Natl Cancer Inst. 2017;109(6):djw294.
   PubMedGoogle Scholar
• Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008;32(9):1299–1309.
   PubMed Web of Science ®Google Scholar
• Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104–e111.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2012;91(4):543–551.
   PubMed Web of Science ®Google Scholar
• Walewski J, Paszkiewicz-Kozik E, Michalski W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the polish lymphoma research group PLRG4. Br J Haematol. 2020;188(6):898–906.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphomas? Hematology Am Soc Hematol Educ Program. 2020;2020(1):295–305.
   PubMedGoogle Scholar
• Kiesewetter B, Ferreri AJM, Raderer M. Chemoimmunotherapy for mucosa-associated lymphoid tissue-type lymphoma: a review of the literature. Oncologist. 2015;20(8):915–925.
   PubMed Web of Science ®Google Scholar
• Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741–748.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Ayala A, McLaughlin P, et al. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized study. Br J Haematol. 2017;177(2):263–270.
   PubMed Web of Science ®Google Scholar
• Kent SA, Variakojis D, Peterson LAC. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol. 2002;117(5):698–708.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95(3):802–806.
   PubMed Web of Science ®Google Scholar